190 related articles for article (PubMed ID: 31011108)
1. p-21 Activated Kinase as a Molecular Target for Chemoprevention in Diabetes.
Dammann K; Khare V; Coleman C; Berdel H; Gasche C
Geriatrics (Basel); 2018 Oct; 3(4):. PubMed ID: 31011108
[TBL] [Abstract][Full Text] [Related]
2. Anti oxidant potential of Metformin and Pioglitazone in Type 2 Diabetes Mellitus: Beyond their anti glycemic effect.
Singh RK; Gupta B; Tripathi K; Singh SK
Diabetes Metab Syndr; 2016; 10(2):102-4. PubMed ID: 26341927
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
4. Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.
Schwartz S
Curr Med Res Opin; 2008 Nov; 24(11):3009-22. PubMed ID: 18828960
[TBL] [Abstract][Full Text] [Related]
5. High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone.
Kim D; Ahn BN; Kim Y; Hur DY; Yang JW; Park GB; Jang JE; Lee EJ; Kwon MJ; Kim TN; Kim MK; Park JH; Rhee BD; Lee SH
J Diabetes Res; 2019; 2019():2376512. PubMed ID: 30729133
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Peng Y; Chen SH; Liu XN; Sun QY
J Cell Physiol; 2019 Mar; 234(3):2795-2806. PubMed ID: 30145806
[TBL] [Abstract][Full Text] [Related]
9. Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Moulton CD; Hopkins CWP; Ismail K; Stahl D
Psychoneuroendocrinology; 2018 Aug; 94():91-103. PubMed ID: 29775878
[TBL] [Abstract][Full Text] [Related]
10. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
Seufert J
Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
Perez A; Zhao Z; Jacks R; Spanheimer R
Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
[TBL] [Abstract][Full Text] [Related]
13. Scutellariae Radix and Coptidis Rhizoma Improve Glucose and Lipid Metabolism in T2DM Rats via Regulation of the Metabolic Profiling and MAPK/PI3K/Akt Signaling Pathway.
Cui X; Qian DW; Jiang S; Shang EX; Zhu ZH; Duan JA
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453687
[No Abstract] [Full Text] [Related]
14. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.
Chilcott J; Tappenden P; Jones ML; Wight JP
Clin Ther; 2001 Nov; 23(11):1792-823; discussion 1791. PubMed ID: 11768834
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
[TBL] [Abstract][Full Text] [Related]
19. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS).
Valsamakis G; Lois K; Kumar S; Mastorakos G
Hormones (Athens); 2013; 12(3):363-78. PubMed ID: 24121378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
